China Stock of the Day | Kabutaro & Friends

Everest Medicines<1952.HK>, a developer of mRNA cancer vaccines, was the Chinese stock most talked about online on August 20, 2026.
Background: On the evening of August 19, 2026 (U.S. time), Moderna and Merck announced that their individualized mRNA cancer vaccine, intismeran autogene, combined with the anti-PD-1 drug Keytruda, met its primary endpoint in a Phase 3 melanoma trial, sending Moderna's stock up about 177%. In response, Hong Kong-listed Everest Medicines, regarded as the purest mRNA play in the region, surged on August 20, 2026, up 68% by the midday close and extending gains to over 70% at one point intraday. The company has its own AI-driven personalized mRNA cancer vaccine pipeline, including EVM16. The rally spread across the sector, with CanSino Biologics up more than 37% and LinkDoc up as much as 130% in Hong Kong, while roughly 26 A-share biopharma stocks, including Watson Bio, CanSino (A-shares), Zhifei Biological, Neobio, and Beijing Bio-Institute, hit their daily 20% limit-up caps. Moderna's market cap rose by USD 44 billion in a single day, and the shift of mRNA technology into oncology drove intense online discussion as a potential turning point for the field.